Actively Recruiting
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
Led by University of California, San Francisco · Updated on 2025-11-12
70
Participants Needed
1
Research Sites
413 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study evaluates an investigational scan called hyperpolarized carbon-13 pyruvate magnetic resonance imaging (MRI) in assessing treatment response in patients with pancreatic ductal carcinoma (PDA) that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). MRI is a standard scan that helps doctors see tumors, organs, tissue, and bone. Standard contrast agents (e.g., gadolinium) are sometimes used to help make the scan images brighter, or easier to see. Hyperpolarized carbon-13 pyruvate is an experimental contrast agent that is different from standard MRI contrast in that it provides information on how a tumor processes nutrients. Hyperpolarized carbon-13 pyruvate MRI scans may work better than MRI with standard contrast agents in predicting how PDA tumors respond to treatment.
CONDITIONS
Official Title
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 18 years or older.
- Histological or cytological confirmation of pancreatic ductal adenocarcinoma (PDA).
- Locally advanced or metastatic disease.
- At least one target lesion in the abdomen measuring 6 1 centimeter, according to RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2 (Karnofsky 6 50%).
- Participants with a prior or concurrent malignancy whose natural history or treatment does not interfere with study safety or endpoints are eligible.
- Ability to understand and willingness to sign a written informed consent document.
You will not qualify if you...
- Unable or unwilling to undergo magnetic resonance imaging (MRI), including contraindications such as cardiac pacemakers or non-compatible intracranial vascular clips.
- Poorly controlled hypertension with systolic > 170 or diastolic > 110, although anti-hypertensive treatment is allowed for eligibility.
- Congestive heart failure Class III or higher.
- Pregnant individuals.
- Breastfeeding or chestfeeding individuals.
- Known allergy to hyperpolarized 13C pyruvate or its ingredients.
- Any condition or social circumstance that impairs ability to comply with study procedures as judged by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
L
Louise Magat
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here